Richard DiMarchi, MBX Biosciences

Suc­cess­ful sci­en­tist-in­vestor al­lies team up again — this time for a stab at rare meta­bol­ic dis­ease

A sci­en­tist-ex­ec­u­tive team that, over the last decade, sold one di­a­betes biotech to Roche for up-to $537 mil­lion and two oth­ers to No­vo Nordisk for undis­closed sums are back with a new com­pa­ny.

Uni­ver­si­ty of In­di­ana bi­ol­o­gist Richard Di­Marchi and se­r­i­al en­tre­pre­neur Kent Hawry­luk have launched MBX Bio­sciences, rais­ing $36.4 mil­lion in a Fra­zier Health­care Part­ners-led round to get it start­ed. For now, the pair are keep­ing their dis­eases and drug tar­gets close to the vest, say­ing on­ly that MBX will de­vel­op the same kind of mol­e­cules they de­vel­oped in pre­vi­ous com­pa­nies — large pep­tide ther­a­peu­tics — but with a fo­cus on rare en­docrine dis­or­ders, as op­posed to di­a­betes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.